author-photo

Javier Pinilla-Ibarz

University of South Florida

332

Papers

6737

Citations

Citation Trend

Filter By

Papers (214) Sort By

Journal Conference Others

Dose Modification Dynamics of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) from the PACE and Optic Trials

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Favorable Outcomes for Patients Treated with U2 with Co-Morbidities or Concomitant Medications: A Retrospective Analysis of Unity-CLL Phase 3 Trial

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Incidence of Pleural Effusion with Dasatinib and the Effect of Switching Therapy to Bosutinib in Patients with Chronic Phase CML

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
FIRST RESULTS OF A HEAD‐TO‐HEAD TRIAL OF ACALABRUTINIB VERSUS IBRUTINIB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA

2021 Hematological Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Abstract CT244: A Phase 1/2 study evaluating the safety and efficacy of IOV-2001 in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)

2021 Clinical Trials
Show All
- Source
- Cite
- Save
Citations (0)
Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma.

2021 JCI insight
Show All
- Source
- Cite
- Save
Citations (0)
Correlates of fatigue severity in patients with chronic myeloid leukemia treated with targeted therapy

2021 Supportive Care in Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Second Treatment Free Remission after Combination Therapy with Ruxolitinib Plus Tyrosine Kinase Inhibitors in Chronic Phase Chronic Myeloid Leukemia (CML)

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
CLL-115: First Results of a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
Trial in Progress: Phase 1/2 Study Evaluating the Safety and Efficacy of Iov-2001, an Autologous, Non-Genetically Modified, Polyclonal T-Cell Product, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)